Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GPR3 | P46089 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080783 | 1.00 | HSD17B10 (1.00) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL85621 | 0.79 | GPR3 (1.00) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL30025532 | 0.78 | ALDH1A1 (0.64) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL27296318 | 0.78 | ALDH1A1 (0.64) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL440157 | 0.78 | ALDH1A1 (0.64) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL196601 | 0.77 | GPR3 (0.64) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL269636 | 0.77 | DCPS (1.00) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL3907848 | 0.77 | GPR3 (0.95) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL29375878 | 0.77 | DCPS (1.00) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 | |
| SCHEMBL28042218 | 0.77 | ALDH1A1 (0.62) | HSD17B10ALDH1A1NUDT1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776492-A | A kind of fluorescence probe and the preparation method and application thereof of the highly selective detection hydrazine of response type | 南京林业大学 | 2019-05-21 | — | — | CN | claimed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| WO-2025068710-A1 | COMPOUNDS COMPRISING AN IMIDAZOLE CORE | Tay Therapeutics Limited (GB) | 2025-04-03 | — | — | WO | disclosed |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2023-01-26 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3514152-B1 | BENZOCARBAZOLE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEMICAL LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| US-11319328-B2 | 4β-amino substituted podophyllotoxin derivative and preparation method therefor and use thereof | Tang, YaJie | 2022-05-03 | — | — | US | disclosed |
| CN-113651820-A | Urea compounds for dual IDO and TDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-1617710-A | Liposome composition for delivery of nucleic acid | ALZA CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1465599-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | HUANG SHI-KUN (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040166150-A1 | Neutral-cationic lipid for systemic delivery of Factor VIII gene | HUANG SHI-KUN (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2003053409-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | ALZA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| WO-2002096390-A1 | NEUTRAL-CATIONIC LIPID FOR SYSTEMIC DELIVERY OF FACTOR VIII GENE | ALZA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-1993013079-A1 | ANTIFOLATE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4333760-A | ARYLSULFONYLURIDOQUINAZOLINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | F13B, F13A1, F8 | HSD17B10 542/4885ALDH1A1 3661/4885NUDT1 4391/4885 |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | HSD17B10 3282/4885ALDH1A1 2665/4885NUDT1 1163/4885 |
| US-11319328-B2 | 4β-amino substituted podophyllotoxin derivative and preparation method therefor and use thereof | WEE1, WEE2, CYP51A1 | HSD17B10 2728/4885ALDH1A1 1581/4885NUDT1 3096/4885 |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | DLST, LIPA, DNAJC10 | HSD17B10 2070/4885ALDH1A1 4380/4885NUDT1 1560/4885 |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | HSD17B10 3838/4885ALDH1A1 4080/4885NUDT1 1086/4885 |
| US-20040166150-A1 | Neutral-cationic lipid for systemic delivery of Factor VIII gene | F8, F13B, F13A1 | HSD17B10 239/4885ALDH1A1 3380/4885NUDT1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.